Introduction
============

Quinoline derivatives such as natural quinine, quinidine, and synthetically produced chloroquine are well known for their use in the treatment of malaria (Figure [1](#F1){ref-type="fig"}). The efficacy of quinine against nocturnal leg cramps has been proven in randomized clinical trials ([@B4]; [@B6]). But the muscle relaxant mechanism of action of quinine has not been fully elucidated yet. As it does not freely cross the blood brain barrier ([@B25]), quinine is supposed to be a peripheral muscle relaxant *in vivo*. In higher dosage as used against malaria, central nervous effects may occur. Quinine and its derivatives are acting on a variety of ion channels including several types of potassium channels ([@B12]; [@B15]), members of family of ligand-gated ion channels such as the 5-HT3-type of serotonin receptor ([@B26]; [@B27]) and nicotinic acetylcholine receptors (nAChR) ([@B9]; [@B2]). Quinine's significant bitterness, widely enjoyed in tonic bitter lemonades, is attributed to activation of bitter taste receptors (T2Rs) which are not limited to taste buds but are expressed in many extraoral tissues ([@B28]). Further, quinolines influence cholinergic synaptic transmission ([@B24]). This effect is possibly the basis for their use in further applications like the treatment of muscle cramps ([@B18]) and slow channel congenital myasthenic syndrome (SCCMS) ([@B13]; [@B14]; [@B21]).

![Left: *Cinchona calisaya* and *Cinchona* bark as the source for quinine. Right: Molecular structures of quinine, quinidine, and chloroquine.](fphar-09-01339-g001){#F1}

It is known that quinine acts on muscular and neuronal nAChRs ([@B24]; [@B8],[@B9]; [@B2]). However, the interaction of quinine has also been reported for receptors present at the neuromuscular junction, in which it produces long-lived open-channel as well as a closed-channel block and can normalize the open duration of channel events in the slow-channel congenital myasthenic syndrome ([@B24]; [@B8],[@B9]). Slow channel congenital myasthenic syndrome (SCCMS) is caused by missense mutations in subunits of nicotinic acetylcholine receptor (AChR) at the neuromuscular junction ([@B7]). Mutated AChR channel produces prolonged opening events leading to a depolarization block and endplate myopathy. Quinoline derivatives such as quinidine correct the prolonged opening times of the mutated acetylcholine receptor channels in myasthenic syndrome ([@B3]). On the contrary, in myasthenia gravis quinine is contraindicated because it decreases the excitability of the motor end-plate region, thereby reducing responses to repetitive nerve stimulation by acetylcholine. These may be the underlying effects explaining the use of low dose quinine in the therapy and prophylaxis of leg cramps.

Quinine is also blocker for the neuronal α9α10 nAChRs. At this cochlear type of ACh receptor, a mixed competitive and non-competitive inhibition was observed ([@B2]). nAChRs form together with 5-HT3-, GABA(A)-, and glycine receptors the superfamily of ligand-gated ion channels ([@B1]). Possibly due the strong structural and functional similarities between these receptors, quinine is also a blocker of 5-HT3- and at elevated concentrations also of GABA(A) receptors ([@B27]).

The composition of muscle nAChRs is dependent of the developmental stage. The fetal nAChR together with the receptor in denervated muscles is composed of αβγδ subunits with a stoichiometry of (α1)~2~β~1~γδ. In the adult, γ is replaced by the 𝜀 subunit ([@B17]). In our present study, we examined the effects of the quinoline derivatives quinine, quinidine, and chloroquine on adult and fetal human muscle nAChRs recombinantly expressed in *X. laevis* oocytes and provide evidence that these compounds block the nAChRs.

Materials and Methods {#s1}
=====================

Expression System
-----------------

The expression plasmids contain the cDNA coding for the different human nAChR subunits in pRBG4 ([@B20]). Cloned muscular AChR subunit cDNAs were kindly provided by Dr A. G. Engel (Mayo Clinic, Rochester, MN, United States) and Dr. F. Grassi (Carattere Scientifico San Raffaele Pisana, Rome, Italy). Cloned cDNA of the human a7 AChR subunit was described by [@B22]. cRNAs were prepared using the AmpliCap T3 high-yield message marker kit (Epicenter, Madison, WI, United States), following the manufacturer's protocol. Oocytes were obtained as previously described ([@B11]) and injected with a total amount of ∼30 ng of a mixture of the receptor-coding cRNA using an injection-setup from WPI (Nanoliter 2000, Micro4). For the muscular type, a mixture of cRNAs for α, β, δ, and 𝜀 in a stoichiometry of 2:1:1:1 was used and for the fetal type, 𝜀 was replaced by γ. The injected oocytes were stored in ND 96 (96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl~2~, 1.0 mM MgCl~2~, 5.0 mM HEPES, pH 7.2, 200 U/ml penicillin, and 200 μg/ml streptomycin) at 12 °C. Measurements were performed 4--6 days after cRNA injection.

Electrophysiology
-----------------

The electrophysiological recordings were performed using the two-electrode voltage clamp technique as previously described ([@B23]). All of the measurements were performed in normal frog ringer (NFR) \[115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl~2~, 10 mM HEPES; pH 7.2 (NaOH/HCl)\]. The currents were recorded at a holding potential of typically -60 mV using the Cell Works 6.1.1. software (NPI).

Substances
----------

The chemicals were obtained from Sigma-Aldrich or Cassella-med GmbH & Co. KG (quinine) and disssolved in NFR.

Data Analysis
-------------

In blocking experiments, the test substances were applied in an alternating manner with ACh. Therefore, the currents of the test substances or the modulated currents were normalized to the mean of the ACh-induced currents before and after the test substance was applied. The concentration-response data were fitted with the logistic equation using SigmaPlot 8.0 (SPSS). The deviations are represented by the standard error of the mean (SEM).

Results
=======

Effect of Quinoline Derivatives on Adult Muscle nAChRs
------------------------------------------------------

For the pharmacological characterization, we expressed the human muscle nAChRs recombinantly in *X. laevis* oocytes and characterized the ion channel activity using the two-electrode voltage-clamp technique. In the first experiments, we established a concentration response curve for ACh on *Xenopus* oocytes expressing the adult nAChR composed of αβγ𝜀 subunits (Figure [2](#F2){ref-type="fig"}). Under our experimental conditions, an EC~50~ value for ACh of 12.65 ± 2.40 μM, n~H~ = 1.77 ± 0.05 (*n* = 6) was determined, similar to the EC~50~ values previously reported in this expression system ([@B16]). Next, we tested the modulatory effects of quinoline derivatives on the response evoked by 10 μM ACh, a near EC~50~ value of the agonist. All three tested quinoline derivatives blocked the ACh-evoked currents in a dose-dependent manner with a potency in the low μM range: quinine was most potent with an IC~50~ of 1.70 ± 0.12 μM (*n* = 6) followed by chloroquine with an IC~50~ of 2.22 ± 0.19 μM (*n* = 6). Quinidine was somehow less potent and blocked with an IC~50~ of 3.96 ± 0.36 μM (*n* = 6) (Figure [3](#F3){ref-type="fig"}). The block by quinine was reversible, as shown in the Supplementary Figure [1A](#SM1){ref-type="supplementary-material"}.

![Concentration-dependent activating effect of ACh on the adult human nicotinic acetylcholine receptor αβ𝜀δ measured in *Xenopus* oocytes. **(A)** Representative membrane currents evoked by ACh measured by two-electrode voltage-clamp. The mean current evoked by 10 μM at the third application was 95% +-. **(B)** Concentration--response curve of the receptor activated by different concentrations of acetylcholine (*n* = 6). Holding potential: --60 mV, error bars represent S.E.M.](fphar-09-01339-g002){#F2}

![Block of adult muscle nicotinic acetylcholine receptor by quinidine and derivatives in *Xenopus* oocytes. **(A)** Representative membrane currents measured by two-electrode voltage-clamp. Currents were elicited by 10 μM ACh in presence of quinine. **(B)** Concentration--inhibition curves for quinine (inverted triangles), quinidine (squares), or chloroquine (circles) at ACh mediated currents elicited by 10 μM ACh in the presence of different concentrations of the blockers (*n* = 6). Holding potential: --60 mV, error bars represent S.E.M.](fphar-09-01339-g003){#F3}

Non-competitive Action of Quinine
---------------------------------

In the rat α9α10 nAChRs, a mixed competitive / non-competitive mode of antagonism for quinine was observed ([@B2]). To determine the mode of antagonism for quinine in the adult muscle nAChRs, we established concentration-response curves for ACh alone and for different concentrations of ACh in the presence of quinine at the same *Xenopus* oocyte. We used 1.8 μM quinine which is a near IC~50~ concentration. In the case of a non-competitive mechanism, the inhibition should be independent of the ACh concentration, whereas the efficacy of competitive antagonists decreases with increasing ACh concentrations. The efficacy of quinine was independent of the ACh concentration (Figure [4A](#F4){ref-type="fig"}) and the determined EC~50~ of ACh didn't significantly change in the presence of 1.8 μM quinine (Figure [4B](#F4){ref-type="fig"}). Further, also at elevated ACh concentrations, the maximally evoked current was never reached in the presence of 1.8 μM quinine (Figure [4B](#F4){ref-type="fig"}).

![ACh concentration--response relationship at human adult muscle nAChRs in the presence and absence of 1.8 μM quinine measured in *Xenopus* oocytes. Currents were elicited by various ACh concentrations. **(A)** Concentration-response curves for human adult muscle nAChRs in the presence (open circles) and the absence (filled circles) of 1.8 μM quinine (*n* = 6). **(B)** Relative current blocked by 1.8 μM quinine at 10, 30, and 100 μM ACh. Holding potential: -60 mV, error bars represent S.E.M.](fphar-09-01339-g004){#F4}

For the rat α9α10 nAChRs a slight voltage dependency of the quinine block was described indicating a potential binding site within or near the channel pore ([@B2]). We tested whether the quinine block of the muscular AChR was also voltage dependent and found that 1.8 μM quinine blocked more pronounced at negative (-60 mV, I/I~max~ = 0.45 ± 0.11, *n* = 3) than at positive membrane potentials (++20 mV, I/I~max~ = 0.87 ± 0.07, *n* = 3) (Supplementary Figure [1C](#SM1){ref-type="supplementary-material"}).

Effect of Quinine on Fetal Muscle and Neuronal nAChRs
-----------------------------------------------------

For the pharmacological characterization, we expressed the fetal muscle nAChRs composed of αβγδ subunits recombinantly in *X. laevis* oocytes and characterized the ion channels using the two-electrode voltage-clamp technique. In the first experiments, we established a concentration response curve for ACh on *Xenopus* oocytes expressing fetal nAChRs (Figure [5](#F5){ref-type="fig"}). Under our experimental conditions, an EC~50~ value for ACh of 7.60 ± 1.87 μM, (*n* = 6) was determined, comparable for the EC~50~ reported for fetal receptors in the *Xenopus* oocyte system ([@B10]). Next, we tested the modulatory effects of quinine on the response evoked by 10 μM ACh, a near EC~50~ value of the agonist, which blocked the ACh-evoked currents in a dose-dependent manner with an IC~50~ of 2.30 ± 0.17 μM (*n* = 3) (Figure [4](#F4){ref-type="fig"}).

![Concentration-dependent activating effect of ACh on the fetal human nicotinic acetylcholine receptor αβγδ measured in *Xenopus* oocytes. **(A)** Concentration--response curve of the receptor activated by different concentrations of acetylcholine (*n* = 6). **(B)** Block of human fetal muscle nAChRs by quinidine in a concentration-dependent manner. Concentration--inhibition curves for quinine (circles) at ACh mediated currents elicited by 10 μM ACh in the presence of different concentrations of the blocker (*n* = 3). Holding potential: -60 mV, error bars represent S.E.M.](fphar-09-01339-g005){#F5}

For the pharmacological characterization of neuronal receptor types, we expressed nAChRs composed of α7 subunits in *X. laevis* oocytes. Under our experimental conditions, the EC~50~ value for ACh was previously reported to be 90.5 μM ([@B22]). We tested the modulatory effects of quinine on the response evoked by 100 μM ACh, a near EC~50~ value of the agonist, which blocked the ACh-evoked currents in a dose-dependent manner with an IC~50~ of 12.8 ± 1.3 μM (*n* = 3) (Supplementary Figure [1B](#SM1){ref-type="supplementary-material"}). The neuronal α7 subtype is of significantly lower potency compared to the muscular type (*p* \< 0.0001).

Discussion
==========

This study describes the effects of quinine, quinidine, and chloroquine on human muscle nAChRs. All three compounds are potent antagonists which block in the low μ-molar range (IC~50~ ∼ 1.7--4 μM) which corresponds to a concentration of 0.6--1.4 mg/l quinine sulfate. Compared with the reported potency at other receptors, quinine shows a similar potency at the neuronal rat α9α10 nAChRs (IC~50~∼1 μM) and the human homomeric 5HT3~A~-receptors (IC~50~∼1 μM), but is less potent at the human neuronal α7 nAChR (IC~50~∼13 μM), the human heteromeric 5HT3~AB~- (IC~50~∼16 μM) or human GABA(A)-receptors (IC~50~∼1.6 mM) ([@B2]; [@B27]). At a similar low μM concentration range the interference with the neuromuscular transmission ([@B24]) or the decrease in the open duration of muscle nAChRs ([@B9]) was observed for quinoline derivatives *in vitro*.

At human muscle nAChRs receptors the observed quinine block was consistent with a non-competitive antagonism. These mode of antagonism for quinine was also reported at human heteromeric 5-HT3~AB~-receptors ([@B27]). At rat neuronal α9α10 nAChRs, quinine was proposed to block competitively at lower, however, non-competitively at higher concentrations ([@B2]). We observed a voltage-dependency for the quinine block of the muscular AChR similar to that reported for the rat α9α10 nAChR. Our results indicate that quinine could interact with a charged side chain within or near the channel pore as discussed in detail for the α9α10 nAChR by [@B2].

Human homomeric 5-HT3~A~ and GABA(A) receptors were blocked in a competitive manner ([@B27]). Binding studies at the recombinant muscle receptor expressed in HEK293 cells support the observed non-competitive antagonism of quinine, as even concentrations up to 30 μM of the antagonist could not inhibit the binding of α-bungarotoxin ([@B24]).

Regarding the high homology between 5-HT3~A~, GABA(A) and nAChRs and the similarities in the actions of quinoline compounds, conserved sites of action for these compounds were suggested ([@B27]).

For the therapy of malaria, an about ten-fold higher oral dosage of quinine is needed than against muscle cramps, and anti-malaria plasma concentrations of 10--15 mg/l are recommended. During acute malaria, quinine plasma concentrations are higher than under non-infectious conditions. Metabolic clearance of quinine in acute illness is reduced because of decreased cytochrome P450 (CYP) 3A4 activity. Increased α-1-acid glycoprotein concentrations in the acute phases of malaria lead to an increased plasma protein binding of quinine, which contributes to the decreased volume of distribution and the increased quinine concentration during the acute phase of the disease ([@B19]). Thus, the *in vitro* observed effects of quinine at central nervous receptors are to be expected in general above a plasma concentration of 10 μg/ml which is not reached after intake of 200--400 mg quinine sulfate against muscle cramps.

When quinine sulfate 2 × 260 mg is applied orally to humans, a dosage which lies in the range used in therapy and prophylaxis of nocturnal leg cramps, a peak plasma concentration of 2.5 μg/ml is reached at about 2 h after intake of quinine. Plasma elimination half time is about 11--12 h; accordingly, plasma concentration was decreased to 1.6 μg/ml after 12 h ([@B5]). These values are in the same concentration range as measured for the inhibitory effect of quinine at the human muscle AChR; thus, this effect may be postulated as a possible mechanism of action of the muscle relaxant effect of quinine which has been therapeutically used in patients with leg cramps for more than half a century.

In summary, we have shown that the quinine, quinidine and chloroquine antagonize ACh-evoked responses at muscular nAChRs. The potency for quinine at the muscle nAChRs was in the same range as found for neuronal rat α9α10 AChR or human 5-HT3~A~-receptors ([@B2]; [@B27]). However, quinine was slightly less potent at the neuronal human α7 AChR.

Typical blood and tissue concentrations for quinine indicate possible action on muscle nAChRs. These observations further extend the pharmacological knowledge on receptors affected by quinoline derivatives. The reversible inhibitory effect of quinine on human muscle nAChRs may be one mechanism which contributes to the clinically proven efficacy of quinine against leg cramps. But as quinine is a wide spectrum channel blocker, further research on its interaction with receptors of different type and location would be of interest.
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